KOSDAQBiotech & Pharma386380

Sky Labs

₩6,910▲ 0.58%2026-11-18 close
Market Cap
₩129.6B
Turnover
₩1.1B
Volume
160K
Shares out.
18.8M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Overseas expansion against persistent losses

Domestic adoption and overseas partnerships are widening, but an operating loss of KRW 5.39 billion through Q3 2026 shows the deficit structure has not yet changed.

  1. 1

    Revenue for the first nine months of 2026 was KRW 197 million, down 43.3% year over year.

  2. 2

    Operating loss reached KRW 5.39 billion and net loss reached KRW 5.61 billion, both wider than the prior-year period.

  3. 3

    Adoption at roughly 2,000 clinics in Korea and rising 24-hour ambulatory blood pressure test prescriptions form the demand base.

  4. 4

    Partnerships with OMRON Healthcare, Otsuka Pharmaceutical and IEM, along with CE-MDR certification, are cited as the basis for overseas expansion.

  5. 5

    The company targets KRW 38.7 billion in revenue and KRW 4.7 billion in operating profit for 2028, while its 2026 revenue target of KRW 10.2 billion is far above the nine-month revenue of KRW 197 million.

02

Business structure

Sky Labs develops ring-type continuous blood pressure monitors and supplies them to clinics and hospitals, with CART BP pro as its main product. The device measures 24-hour blood pressure changes during daily life.

Revenue comes from device sales: the company supplies CART devices to distributors such as Daewoong Pharmaceutical, which then sell them to medical institutions. The domestic distribution and rights agreement with Daewoong dates from June 2023.

As of June 2026, the product had been introduced at roughly 2,000 clinics and hospitals across Korea, and after health insurance reimbursement the test fee is about KRW 18,000 per test, with patients paying about KRW 5,000 to 6,000.

The lineup expanded with the consumer model CART BP in September 2025 and the ward model CART ON in January 2026. Through the CART NET medical data platform, the company plans to extend into pharmaceutical clinical work and medical AI.

Overseas, OMRON Healthcare, which holds about 50% of the global blood pressure monitor market, invested KRW 3.5 billion in November 2025 and is a partner, and a distribution agreement is in place with Otsuka Pharmaceutical in Japan.

Competitive positioning rests on the continuous ring format, health insurance coverage and partner distribution networks.

03

Recent trends

Based on DART filings, revenue for the first nine months of 2026 was KRW 197 million, down 43.3% from the same period a year earlier. Operating loss for the same period was KRW 5.39 billion and net loss was KRW 5.61 billion, with losses widening versus the prior-year period.

According to the audit report, 2025 revenue was about KRW 794.5 million, up roughly 94.3% from 2024, while the 2025 operating loss widened to KRW 14.7 billion from KRW 11.7 billion in 2024. The revenue increase is mainly attributed to health insurance reimbursement for CART BP pro.

Press reports based on the securities registration statement said first-half 2026 revenue was about KRW 5.0 billion, with overseas sales at 52% of the total. Press and filing figures may follow different aggregation bases, so they should be read with care.

Shares closed on the first trading day on September 4, 2026 at KRW 23,500, up 135.0% from the offer price, and hit the daily upper limit on the next trading day.

Market data from early October 2026 showed a price of KRW 18,020, and the price as of 06:55 KST on November 18, 2026 was KRW 6,940, down 2.80% from the previous close. Market capitalization is KRW 130.2 billion and trading value is KRW 700 million. As of September 2026, major shareholders were the Korea Development Bank (6.53%) and IMM (6.44%).

04

Outlook

The company's stated targets are revenue of KRW 10.2 billion and an operating loss of KRW 15.4 billion for 2026, revenue of KRW 18.8 billion and an operating loss of KRW 10.4 billion for 2027, and revenue of KRW 38.7 billion and operating profit of KRW 4.7 billion for 2028.

For 2030 it targets revenue of KRW 78.0 billion and operating profit of KRW 30.5 billion. These are management projections. Set against the nine-month revenue of KRW 197 million in DART filings, the 2026 revenue target would require heavy concentration of sales in the fourth quarter.

The 2028 break-even depends on overseas sales ramping through IEM, OMRON and Otsuka distribution networks and on US FDA approval and commercialization.

On the US side, protocol discussions with the FDA are complete, and the company targets FDA approval by the end of 2027, with a clinical protocol covering 305 subjects across three US research sites.

Product extensions include the oxygen saturation device CART O2 and the integrated vital sign monitor CART Vital, which are slated for sequential launch.

The performance indicators the company itself named are the share of CART devices in hospital-based ambulatory blood pressure testing in Korea, overseas sales and their share, and the scale of data platform partnerships. Whether the 2026 revenue target is met and when break-even arrives will be checked against future filings.

05

Bull factors

Overseas distribution partners secured

Press reports based on the securities registration statement put overseas sales at 52% of first-half 2026 revenue. In Europe, a supply agreement with IEM supports entry into clinics in the UK and Germany.

In Japan, Otsuka Pharmaceutical plans to supply Japanese medical institutions from 2028, and discussions on using OMRON's pharmacy and consumer channels are underway.

Domestic prescription base and reimbursement effect

The company said that as of June 2026, the product had been adopted by roughly 2,000 clinics and hospitals in Korea, including all top five hospitals and 38 of 47 tertiary hospitals. Total 24-hour ambulatory blood pressure test prescriptions in Korea rose 52.7% in the year after CART BP pro's launch. The company said CART BP pro accounted for 52.4% of those tests.

Certifications and data assets

The company said it obtained CE MDR certification in January 2026 and completed MHRA registration and appointed a UK responsible person. It is also pursuing a data business that uses biosignals collected by its devices for research, and CART NET is being used in a cohort study by the National Institute of Health.

The company has also highlighted its selection as the only Korean medical device and wearable company on TIME's 2026 list of the world's top 500 health technology companies.

06

Bear factors

Persistent and widening losses

DART filings show operating loss of KRW 5.39 billion and net loss of KRW 5.61 billion for the first nine months of 2026, both wider than a year earlier. The 2025 operating loss widened to KRW 14.7 billion from KRW 11.7 billion in 2024.

The company expects a 2026 operating loss of KRW 15.4 billion and targets break-even in 2028. Losses have not narrowed despite revenue growth, so cost and SG&A structure remains a key point to confirm in future filings.

Small revenue base and figure gaps

Revenue for the first nine months of 2026 in DART filings was KRW 197 million, down 43.3% year over year. By contrast, press reports based on the securities registration statement put first-half 2026 revenue at about KRW 5.0 billion.

Because the two may use different bases, the 52% overseas share should be read as a press-reported figure. With a small revenue base, a higher overseas share could also make quarterly results more volatile.

Clinical evidence and share price volatility

A clinical comparison study cited in press coverage was not randomized, and its researchers said randomized trials are needed before the observed blood pressure differences can be attributed to the device.

Shares moved sharply, from a KRW 23,500 close on the listing day to KRW 18,020 in early October 2026 and KRW 6,940 on November 18, 2026. With trading value around KRW 700 million, price moves may be sensitive to supply and demand.

07

Risk factors

Macro

Newly listed stocks tend to be sensitive to changes in KOSDAQ-wide liquidity and sentiment. With low trading value, even modest shifts in supply and demand can move the price substantially. As overseas sales become a larger share, changes in foreign exchange conditions could also affect how results are read.

Regulatory

The US FDA approval target is the end of 2027, and it depends on completing local clinical work. The hospital version in Japan is still going through local device approval, and entry into the UK National Health Service market is still being pursued. Delays in approvals would push back the conditions behind the 2028 break-even target.

Distribution dependence

Revenue depends on device orders from domestic distributors such as Daewoong Pharmaceutical and on supply volumes through overseas partners including OMRON, Otsuka and IEM. Quarterly revenue can shift significantly with distributors' order timing and inventory policies. As the partner base widens, it will be necessary to track each partner's contribution in future filings.

08

Overall view

Sky Labs is expanding its domestic prescription base for its ring-type blood pressure monitor and its overseas distribution partnerships at the same time.

DART filings show that revenue for the first nine months of 2026 fell to KRW 197 million, while the operating loss of KRW 5.39 billion and net loss of KRW 5.61 billion widened.

On the strengths side, the number of clinics adopting the product, the rise in prescriptions, European certification and the partner lineup are cited as the basis for expansion.

On the weaknesses side, the key issues are continuing losses, a small revenue base, the gap between press and filing figures, and limits in the clinical evidence.

The 2028 break-even target assumes overseas sales scale up and US FDA approval is obtained, so whether those assumptions are confirmed in future filings is the central point. The gap between the 2026 full-year revenue target and nine-month revenue will be tested by how much sales concentrate in the fourth quarter.

The share price has moved widely since listing, and low trading value means it may react sharply to supply and demand.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. digitalchosun.dizzo.com
  2. aipostkorea.com
  3. view.asiae.co.kr
  4. fnnews.com
  5. thebionews.net
  6. thebionews.net
  7. m.news.nate.com
  8. edaily.co.kr
  9. m.sedaily.com
  10. skylabs.io
  11. kr.investing.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis